oseltamivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals neuraminidase inhibitors	2001	196618-13-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ebilfumin oseltamivir tamvir tamiflu oseltamivir phosphate	Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. The median IC50 values of oseltamivir against influenza A/H1N1, influenza A/H3N2, and influenza B clinical isolates were 2.5 nM (range 0.93-4.16 nM, N=74), 0.96 nM (range 0.13 - 7.95 nM, N=774), and 60 nM (20-285 nM, N=256), respectively, in a neuraminidase assay with a fluorescently labeled MUNANA substrate. Although oseltamivir was suggested as a potential treatment and included in various antiviral regimens used during the early stages of the COVID-19 pandemic, the drug does not appear to have in vitro activity against SARS-CoV-2 and there are no data to support the use of oseltamivir or other neuraminidase inhibitors in the treatment of COVID-19. Molecular weight: 312.41 Formula: C16H28N2O4 CLOGP: 2.13 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 90.65 ALOGS: -2.66 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ebilfumin
oseltamivir
tamvir
tamiflu
oseltamivir phosphate

Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. The median IC50 values of oseltamivir against influenza A/H1N1, influenza A/H3N2, and influenza B clinical isolates were 2.5 nM (range 0.93-4.16 nM, N=74), 0.96 nM (range 0.13 - 7.95 nM, N=774), and 60 nM (20-285 nM, N=256), respectively, in a neuraminidase assay with a fluorescently labeled MUNANA substrate. Although oseltamivir was suggested as a potential treatment and included in various antiviral regimens used during the early stages of the COVID-19 pandemic, the drug does not appear to have in vitro activity against SARS-CoV-2 and there are no data to support the use of oseltamivir or other neuraminidase inhibitors in the treatment of COVID-19.

Molecular weight: 312.41
Formula: C16H28N2O4
CLOGP: 2.13
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 90.65
ALOGS: -2.66
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.15	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	99 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.71 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	1.60 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.74 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
June 20, 2002	EMA	Roche Registration GmbH
Oct. 27, 1999	FDA	ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
No adverse event	996.02	14.82	400	19099	41005	63428518
Exposure during pregnancy	668.51	14.82	475	19024	155072	63314451
Pregnancy	590.06	14.82	267	19232	36569	63432954
Abnormal behaviour	552.82	14.82	218	19281	21208	63448315
Hallucination	197.56	14.82	151	19348	54666	63414857
Influenza	174.38	14.82	190	19309	108532	63360991
Premature delivery	149.41	14.82	101	19398	30180	63439343
Enterocolitis haemorrhagic	144.47	14.82	41	19458	1425	63468098
Pulmonary function test abnormal	139.79	14.82	42	19457	1788	63467735
Chest X-ray abnormal	130.34	14.82	50	19449	4499	63465024
Off label use	123.19	14.82	469	19030	673993	62795530
Ear pruritus	122.33	14.82	46	19453	3919	63465604
Normal newborn	119.38	14.82	56	19443	8285	63461238
Blood lactic acid increased	105.83	14.82	49	19450	7037	63462486
Acute respiratory distress syndrome	105.48	14.82	74	19425	23460	63446063
Pathogen resistance	104.23	14.82	47	19452	6351	63463172
Nasal polyps	100.40	14.82	45	19454	5994	63463529
Rhinitis allergic	85.19	14.82	50	19449	11677	63457846
Sneezing	78.65	14.82	56	19443	18162	63451361
Breath sounds abnormal	77.65	14.82	46	19453	10927	63458596
Maternal exposure during pregnancy	76.45	14.82	192	19307	219870	63249653
Vasculitis	76.38	14.82	55	19444	18154	63451369
Platelet count increased	73.16	14.82	53	19446	17658	63451865
Upper-airway cough syndrome	70.85	14.82	44	19455	11374	63458149
Respiratory failure	68.81	14.82	117	19382	101741	63367782
Seizure	66.52	14.82	134	19365	132500	63337023
Respiratory syncytial virus infection	61.97	14.82	34	19465	6984	63462539
Eye pruritus	59.77	14.82	48	19451	18623	63450900
Pneumonia	56.41	14.82	283	19216	456484	63013039
Alopecia	56.12	14.82	17	19482	337519	63132004
Drug ineffective for unapproved indication	55.32	14.82	60	19439	34003	63435520
Full blood count abnormal	53.50	14.82	57	19442	31660	63437863
Delirium	52.55	14.82	71	19428	50470	63419053
Systemic lupus erythematosus	52.07	14.82	3	19496	208915	63260608
Fatigue	51.57	14.82	124	19375	887904	62581619
Lacrimation increased	51.57	14.82	46	19453	20585	63448938
Eosinophilia	51.52	14.82	48	19451	22708	63446815
Pneumonia influenzal	49.86	14.82	19	19480	1678	63467845
Excessive eye blinking	47.44	14.82	17	19482	1263	63468260
Therapeutic product effect decreased	44.62	14.82	4	19495	193183	63276340
Synovitis	42.83	14.82	4	19495	186914	63282609
Rhinorrhoea	42.51	14.82	74	19425	65503	63404020
Swelling	42.06	14.82	16	19483	275362	63194161
Pain	41.68	14.82	105	19394	740523	62729000
Treatment failure	41.28	14.82	6	19493	199037	63270486
Foetal exposure during pregnancy	41.26	14.82	50	19449	31912	63437611
Premature baby	39.90	14.82	40	19459	20695	63448828
Joint swelling	39.59	14.82	26	19473	327640	63141883
International normalised ratio increased	39.10	14.82	59	19440	46366	63423157
Stevens-Johnson syndrome	38.86	14.82	43	19456	24907	63444616
Blood potassium decreased	37.68	14.82	55	19444	41971	63427552
Vomiting	37.18	14.82	296	19203	559321	62910202
H1N1 influenza	35.57	14.82	15	19484	1724	63467799
Hepatitis infectious mononucleosis	35.28	14.82	8	19491	109	63469414
Toxicity to various agents	35.11	14.82	16	19483	247234	63222289
Completed suicide	33.68	14.82	3	19496	145670	63323853
Loss of consciousness	32.82	14.82	95	19404	118026	63351497
Discomfort	32.57	14.82	6	19493	167368	63302155
Swollen tongue	31.86	14.82	46	19453	34754	63434769
Infusion related reaction	31.71	14.82	18	19481	245503	63224020
Asthma	30.21	14.82	97	19402	127464	63342059
Respiratory distress	29.81	14.82	44	19455	33907	63435616
Weight increased	29.75	14.82	22	19477	260770	63208753
Peripheral swelling	29.62	14.82	23	19476	265919	63203604
Hypothermia	29.50	14.82	28	19471	13553	63455970
Glomerulonephritis minimal lesion	29.09	14.82	8	19491	247	63469276
Colitis ischaemic	29.01	14.82	25	19474	10683	63458840
Abortion spontaneous	27.69	14.82	51	19448	47144	63422379
Wheezing	27.63	14.82	78	19421	95517	63374006
Primary myelofibrosis	26.94	14.82	6	19493	75	63469448
Purpura senile	26.75	14.82	9	19490	554	63468969
Atelectasis	26.74	14.82	33	19466	21450	63448073
Accidental overdose	26.15	14.82	34	19465	23275	63446248
Product use issue	25.94	14.82	18	19481	220502	63249021
Iris transillumination defect	25.45	14.82	6	19493	98	63469425
Delirium febrile	25.45	14.82	5	19494	32	63469491
Bronchopleural fistula	25.40	14.82	7	19492	218	63469305
Hallucination, auditory	25.15	14.82	25	19474	12799	63456724
Hypoxia	24.84	14.82	56	19443	59736	63409787
Angioedema	24.65	14.82	49	19450	47916	63421607
Wound	24.06	14.82	10	19489	163253	63306270
Idiosyncratic drug reaction	23.35	14.82	9	19490	819	63468704
Tarsal tunnel syndrome	22.70	14.82	8	19491	566	63468957
Abdominal discomfort	22.57	14.82	40	19459	320845	63148678
Influenza A virus test positive	22.40	14.82	7	19492	340	63469183
Rheumatoid arthritis	22.39	14.82	27	19472	253792	63215731
Hypertension	22.30	14.82	32	19467	279271	63190252
Mobility decreased	22.20	14.82	5	19494	121154	63348369
Low birth weight baby	22.12	14.82	18	19481	7111	63462412
Abortion induced	22.02	14.82	21	19478	10221	63459302
Agitation	21.59	14.82	53	19446	59704	63409819
Swelling face	21.57	14.82	55	19444	63420	63406103
Screaming	21.33	14.82	13	19486	3249	63466274
Neonatal pneumonia	21.19	14.82	4	19495	20	63469503
Hepatitis fulminant	20.61	14.82	13	19486	3451	63466072
Nasal congestion	20.38	14.82	55	19444	65605	63403918
Erythema multiforme	20.27	14.82	20	19479	10149	63459374
Toxic epidermal necrolysis	19.65	14.82	31	19468	25303	63444220
Hepatic enzyme increased	19.51	14.82	20	19479	202308	63267215
Glossodynia	19.24	14.82	16	19483	178860	63290663
Delusion	19.21	14.82	21	19478	11996	63457527
Foetal growth restriction	19.19	14.82	17	19482	7536	63461987
Tachypnoea	19.04	14.82	25	19474	17277	63452246
Vestibular disorder	18.62	14.82	9	19490	1422	63468101
Altered state of consciousness	18.37	14.82	30	19469	25200	63444323
Drug-induced liver injury	18.21	14.82	39	19460	40183	63429340
Infantile apnoea	18.14	14.82	8	19491	1025	63468498
Pericarditis	17.92	14.82	9	19490	131570	63337953
Chest discomfort	17.86	14.82	74	19425	109895	63359628
Right atrial dilatation	17.83	14.82	7	19492	670	63468853
Blood viscosity abnormal	17.75	14.82	5	19494	169	63469354
Overdose	17.57	14.82	76	19423	115002	63354521
Hypercapnia	17.46	14.82	14	19485	5417	63464106
Urticaria	17.14	14.82	98	19401	165704	63303819
Resorption bone increased	16.54	14.82	8	19491	1266	63468257
Legionella infection	16.51	14.82	6	19493	464	63469059
Dysphoria	16.39	14.82	13	19486	4953	63464570
Psoriatic arthropathy	16.32	14.82	4	19495	91516	63378007
Drug effective for unapproved indication	16.05	14.82	11	19488	3353	63466170
Thinking abnormal	15.98	14.82	18	19481	10625	63458898
Arthralgia	15.97	14.82	106	19393	569604	62899919
Lymphocyte stimulation test positive	15.93	14.82	6	19493	513	63469010
Irritable bowel syndrome	15.93	14.82	3	19496	82409	63387114
Dysphonia	15.91	14.82	41	19458	47573	63421950
Nasopharyngitis	15.87	14.82	34	19465	254223	63215300
Haemorrhagic diathesis	15.52	14.82	12	19487	4403	63465120
Selective eating disorder	15.48	14.82	9	19490	2063	63467460
Stomatitis	15.43	14.82	12	19487	138713	63330810
Cough	15.26	14.82	147	19352	292596	63176927
Premature labour	15.23	14.82	19	19480	12485	63457038
Infective pulmonary exacerbation of cystic fibrosis	15.14	14.82	16	19483	8801	63460722
Viral myocarditis	15.03	14.82	5	19494	297	63469226
Caesarean section	14.84	14.82	22	19477	17010	63452513

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abnormal behaviour	1100.85	15.77	410	14572	24559	34917390
Normal newborn	319.99	15.77	57	14925	122	34941827
Off label use	247.12	15.77	548	14434	418976	34522973
Appendicolith	227.46	15.77	98	14884	8503	34933446
Hallucination	210.20	15.77	175	14807	51323	34890626
Influenza	201.08	15.77	168	14814	49498	34892451
No adverse event	178.08	15.77	115	14867	22812	34919137
Appendicitis	176.87	15.77	98	14884	14709	34927240
Delirium	170.19	15.77	145	14837	43846	34898103
Blood phosphorus increased	156.32	15.77	73	14909	7648	34934301
Ventricular fibrillation	144.33	15.77	101	14881	22853	34919096
Cardiogenic shock	137.54	15.77	104	14878	26514	34915435
Pathogen resistance	119.39	15.77	65	14917	9417	34932532
Stress	119.28	15.77	101	14881	30246	34911703
Multiple organ dysfunction syndrome	115.85	15.77	153	14829	76413	34865536
Exposure during pregnancy	98.15	15.77	56	14926	8878	34933071
Ascites	87.87	15.77	104	14878	46467	34895482
Vomiting	87.27	15.77	268	14714	247353	34694596
Abdominal distension	82.48	15.77	113	14869	58379	34883570
Pneumonia influenzal	70.39	15.77	26	14956	1502	34940447
Dry mouth	68.16	15.77	74	14908	30091	34911858
Hyponatraemia	59.60	15.77	118	14864	82573	34859376
Myasthenia gravis	59.29	15.77	37	14945	6903	34935046
Blood uric acid increased	55.04	15.77	40	14942	9584	34932365
Sepsis	52.77	15.77	174	14808	166387	34775562
JC virus infection	51.35	15.77	23	14959	2185	34939764
Hallucination, visual	49.84	15.77	49	14933	17742	34924207
Seizure	48.03	15.77	125	14857	104732	34837217
Acute respiratory distress syndrome	44.07	15.77	55	14927	25914	34916035
Pneumonia	41.97	15.77	282	14700	362345	34579604
Bronchopulmonary aspergillosis	40.36	15.77	40	14942	14619	34927330
Fatigue	37.90	15.77	63	14919	370590	34571359
Analgesic therapy	35.27	15.77	14	14968	984	34940965
Drug therapy	33.46	15.77	14	14968	1127	34940822
Rash morbilliform	32.96	15.77	19	14963	3068	34938881
Blood cholesterol increased	32.46	15.77	42	14940	20501	34921448
Sleep terror	32.28	15.77	17	14965	2301	34939648
Influenza A virus test positive	31.77	15.77	9	14973	220	34941729
Toxicity to various agents	31.41	15.77	24	14958	200338	34741611
Abdominal pain	31.39	15.77	146	14836	163472	34778477
Hyperphosphataemia	31.35	15.77	21	14961	4416	34937533
Sleep disorder therapy	28.16	15.77	12	14970	1011	34940938
Porphyria acute	28.08	15.77	9	14973	338	34941611
Incorrect route of product administration	27.71	15.77	33	14949	14812	34927137
Depressed level of consciousness	27.13	15.77	58	14924	42783	34899166
Nightmare	26.88	15.77	32	14950	14359	34927590
Toxic epidermal necrolysis	26.31	15.77	39	14943	21607	34920342
Crying	26.11	15.77	21	14961	5841	34936108
Constipation	26.08	15.77	122	14860	136860	34805089
Bacterial infection	25.59	15.77	34	14948	17029	34924920
Urinary tract inflammation	24.79	15.77	7	14975	169	34941780
Weight decreased	24.12	15.77	24	14958	176277	34765672
Hypotension	23.22	15.77	37	14945	221612	34720337
Condition aggravated	23.04	15.77	151	14831	192045	34749904
Neuropsychiatric symptoms	22.92	15.77	10	14972	892	34941057
Somnolence	22.65	15.77	101	14881	111015	34830934
Aspergillus infection	22.47	15.77	27	14955	12227	34929722
Hepatitis cholestatic	22.46	15.77	22	14960	7925	34934024
Drug resistance	22.37	15.77	40	14942	25887	34916062
H1N1 influenza	22.30	15.77	10	14972	952	34940997
Enterocolitis haemorrhagic	22.09	15.77	10	14972	973	34940976
General physical health deterioration	22.08	15.77	111	14871	128158	34813791
Hypothermia	21.91	15.77	25	14957	10723	34931226
Lymphocyte stimulation test positive	21.67	15.77	9	14973	711	34941238
Dizziness	21.48	15.77	38	14944	218483	34723466
Iron deficiency	21.30	15.77	18	14964	5363	34936586
Drug reaction with eosinophilia and systemic symptoms	21.25	15.77	45	14937	32967	34908982
Congenital heart valve disorder	21.21	15.77	5	14977	57	34941892
Central vision loss	20.80	15.77	4	14978	15	34941934
Pain	20.66	15.77	35	14947	204640	34737309
Oedema peripheral	20.54	15.77	13	14969	119799	34822150
Progressive multifocal leukoencephalopathy	20.39	15.77	23	14959	9741	34932208
Foetal exposure during pregnancy	20.12	15.77	48	14934	38053	34903896
Hallucination, auditory	19.83	15.77	25	14957	11892	34930057
Hypertension	19.32	15.77	18	14964	136425	34805524
Cardiac failure congestive	19.02	15.77	6	14976	83264	34858685
Respiratory failure	18.70	15.77	94	14888	108478	34833471
Delirium febrile	18.14	15.77	4	14978	33	34941916
Agitation	18.14	15.77	60	14922	57339	34884610
Malignant neoplasm progression	17.36	15.77	8	14974	88038	34853911
Arthralgia	17.22	15.77	29	14953	170012	34771937
Caesarean section	17.14	15.77	11	14971	2153	34939796
Conductive deafness	17.00	15.77	6	14976	304	34941645
Neck injury	16.92	15.77	9	14973	1242	34940707
Premature baby	16.57	15.77	30	14952	19603	34922346
Nausea	16.55	15.77	220	14762	339688	34602261
Hepatitis fulminant	16.55	15.77	14	14968	4176	34937773
Febrile convulsion	16.09	15.77	7	14975	620	34941329
Overdose	15.79	15.77	79	14903	90980	34850969

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abnormal behaviour	1437.04	14.41	530	28814	35891	79679153
No adverse event	529.12	14.41	263	29081	36929	79678115
Off label use	407.70	14.41	972	28372	906243	78808801
Exposure during pregnancy	370.83	14.41	303	29041	100829	79614215
Hallucination	340.00	14.41	269	29075	85476	79629568
Influenza	271.36	14.41	284	29060	129322	79585722
Appendicolith	238.85	14.41	97	29247	8454	79706590
Pathogen resistance	238.70	14.41	113	29231	14229	79700815
Delirium	187.01	14.41	191	29153	84436	79630608
Appendicitis	183.08	14.41	107	29237	20687	79694357
Blood phosphorus increased	149.46	14.41	74	29270	10273	79704771
Enterocolitis haemorrhagic	148.94	14.41	48	29296	2146	79712898
Ventricular fibrillation	132.51	14.41	103	29241	31823	79683221
Acute respiratory distress syndrome	130.60	14.41	117	29227	43950	79671094
Premature delivery	125.03	14.41	88	29256	23379	79691665
Cardiogenic shock	115.82	14.41	107	29237	41807	79673237
Ear pruritus	112.58	14.41	46	29298	4069	79710975
Multiple organ dysfunction syndrome	111.54	14.41	176	29168	120070	79594974
Seizure	103.42	14.41	220	29124	188614	79526430
Chest X-ray abnormal	101.03	14.41	52	29292	7831	79707213
Pulmonary function test abnormal	98.81	14.41	42	29302	4102	79710942
Pneumonia influenzal	95.24	14.41	37	29307	2867	79712177
Pneumonia	92.84	14.41	483	28861	659763	79055281
Fatigue	87.10	14.41	130	29214	929597	78785447
Vomiting	85.38	14.41	475	28869	665353	79049691
Nasal polyps	81.59	14.41	44	29300	7283	79707761
Respiratory syncytial virus infection	76.51	14.41	46	29298	9356	79705688
Pregnancy	75.05	14.41	69	29275	26782	79688262
Rhinitis allergic	74.78	14.41	50	29294	12219	79702825
Respiratory failure	72.96	14.41	187	29157	180724	79534320
Blood lactic acid increased	70.70	14.41	49	29295	12695	79702349
Ascites	70.58	14.41	111	29233	75451	79639593
Toxicity to various agents	69.76	14.41	34	29310	421506	79293538
Drug ineffective for unapproved indication	69.62	14.41	90	29254	51148	79663896
Maternal exposure during pregnancy	67.80	14.41	153	29191	136385	79578659
Sneezing	61.76	14.41	54	29290	19629	79695415
Breath sounds abnormal	60.79	14.41	49	29295	15935	79699109
Upper-airway cough syndrome	60.31	14.41	43	29301	11650	79703394
Myasthenia gravis	57.73	14.41	40	29304	10359	79704685
Stress	57.16	14.41	104	29240	79508	79635536
Platelet count increased	55.77	14.41	54	29290	22352	79692692
Influenza A virus test positive	54.41	14.41	17	29327	686	79714358
Pain	52.63	14.41	113	29231	703689	79011355
H1N1 influenza	51.80	14.41	23	29321	2496	79712548
Hallucination, visual	51.68	14.41	62	29282	32667	79682377
Vasculitis	50.62	14.41	54	29290	25048	79689996
Blood uric acid increased	48.79	14.41	40	29304	13320	79701724
Therapeutic product effect decreased	48.35	14.41	3	29341	163860	79551184
Alopecia	47.79	14.41	13	29331	231342	79483702
Hypothermia	47.77	14.41	50	29294	22696	79692348
Sepsis	47.72	14.41	211	29133	269217	79445827
Abdominal distension	46.47	14.41	122	29222	119528	79595516
Lacrimation increased	44.70	14.41	48	29296	22429	79692615
Eye pruritus	44.60	14.41	46	29298	20524	79694520
Stevens-Johnson syndrome	44.38	14.41	63	29281	39103	79675941
Hyponatraemia	44.23	14.41	155	29189	177693	79537351
Completed suicide	43.47	14.41	18	29326	245749	79469295
Excessive eye blinking	43.09	14.41	18	29326	1683	79713361
JC virus infection	42.36	14.41	23	29321	3858	79711186
Toxic epidermal necrolysis	42.32	14.41	66	29278	44515	79670529
Loss of consciousness	42.31	14.41	147	29197	167796	79547248
Weight increased	42.00	14.41	25	29319	277361	79437683
Synovitis	40.99	14.41	4	29340	150730	79564314
International normalised ratio increased	39.89	14.41	93	29251	84628	79630416
Bronchopulmonary aspergillosis	39.82	14.41	45	29299	22249	79692795
Lymphocyte stimulation test positive	39.16	14.41	15	29329	1118	79713926
Analgesic therapy	37.19	14.41	14	29330	995	79714049
Hyperphosphataemia	36.51	14.41	25	29319	6351	79708693
Colitis ischaemic	36.32	14.41	36	29308	15323	79699721
Overdose	36.25	14.41	149	29195	184057	79530987
Infusion related reaction	35.92	14.41	20	29324	230217	79484827
Full blood count abnormal	35.78	14.41	58	29286	40416	79674628
Hallucination, auditory	35.66	14.41	41	29303	20652	79694392
Accidental overdose	35.37	14.41	57	29287	39524	79675520
Hypertension	35.19	14.41	42	29302	330950	79384094
Drug therapy	34.82	14.41	14	29330	1187	79713857
Hepatitis fulminant	33.58	14.41	25	29319	7237	79707807
Systemic lupus erythematosus	33.51	14.41	3	29341	121146	79593898
Depressed level of consciousness	32.98	14.41	94	29250	96558	79618486
Joint swelling	32.45	14.41	35	29309	288611	79426433
Contraindicated product administered	32.25	14.41	9	29335	157529	79557515
Peripheral swelling	32.23	14.41	31	29313	269586	79445458
Hepatitis infectious mononucleosis	31.45	14.41	8	29336	150	79714894
Rhinorrhoea	31.00	14.41	79	29265	75995	79639049
Sleep disorder therapy	29.91	14.41	12	29332	1012	79714032
Nightmare	29.89	14.41	42	29302	25819	79689225
Aspergillus infection	29.76	14.41	36	29308	19125	79695919
Delusion	29.51	14.41	37	29307	20386	79694658
Hypotension	29.39	14.41	75	29269	440242	79274802
Treatment failure	29.32	14.41	13	29331	170473	79544571
Weight decreased	29.07	14.41	54	29290	355144	79359900
Mobility decreased	29.00	14.41	5	29339	122170	79592874
Restlessness	28.74	14.41	57	29287	46435	79668609
Agitation	28.40	14.41	91	29253	99624	79615420
Drug resistance	27.60	14.41	53	29291	42160	79672884
Arthralgia	26.70	14.41	114	29230	571689	79143355
Product use issue	26.41	14.41	23	29321	209799	79505245
Delirium febrile	25.86	14.41	6	29338	75	79714969
Abdominal pain	25.66	14.41	237	29107	389332	79325712
Blood potassium decreased	25.19	14.41	54	29290	46458	79668586
Myocardial infarction	24.64	14.41	19	29325	184110	79530934
Nasopharyngitis	24.12	14.41	35	29309	253846	79461198
Screaming	23.90	14.41	16	29328	3917	79711127
Psychiatric symptom	23.49	14.41	20	29324	7015	79708029
Atelectasis	22.96	14.41	42	29302	32215	79682829
Dizziness	22.74	14.41	108	29236	526333	79188711
Erythema multiforme	22.41	14.41	30	29314	17621	79697423
Constipation	22.18	14.41	179	29165	282871	79432173
Purpura senile	21.91	14.41	8	29336	522	79714522
Iris transillumination defect	21.84	14.41	6	29338	153	79714891
Tarsal tunnel syndrome	21.82	14.41	8	29336	528	79714516
Primary myelofibrosis	21.80	14.41	6	29338	154	79714890
Rash morbilliform	21.59	14.41	18	29326	6132	79708912
Cardiac failure congestive	21.31	14.41	13	29331	142389	79572655
Respiratory distress	21.14	14.41	58	29286	58281	79656763
Asthma	21.07	14.41	102	29242	134993	79580051
Discomfort	20.94	14.41	10	29334	125607	79589437
Nosocomial infection	20.85	14.41	13	29331	2819	79712225
Encephalitis influenzal	20.72	14.41	3	29341	0	79715044
Eosinophilia	20.49	14.41	49	29295	45296	79669748
Central vision loss	20.15	14.41	4	29340	22	79715022
Neuropsychiatric symptoms	20.07	14.41	10	29334	1405	79713639
Hepatitis cholestatic	19.86	14.41	25	29319	13827	79701217
Infective pulmonary exacerbation of cystic fibrosis	19.72	14.41	24	29320	12827	79702217
Hepatic enzyme increased	19.57	14.41	23	29321	182587	79532457
Dry mouth	19.56	14.41	74	29270	87945	79627099
Conductive deafness	19.28	14.41	6	29338	239	79714805
Hypoxia	19.11	14.41	82	29262	103161	79611883
Urinary tract inflammation	18.93	14.41	6	29338	254	79714790
Bacterial infection	18.91	14.41	38	29306	31242	79683802
Abdominal discomfort	18.88	14.41	40	29304	250687	79464357
Glomerulonephritis minimal lesion	18.84	14.41	8	29336	779	79714265
Altered state of consciousness	18.36	14.41	46	29298	43776	79671268
Wound	18.24	14.41	10	29334	116169	79598875
Malignant neoplasm progression	18.23	14.41	14	29330	135976	79579068
Swollen tongue	18.17	14.41	45	29299	42525	79672519
Migraine	17.90	14.41	5	29339	87488	79627556
Pericarditis	17.83	14.41	8	29336	104228	79610816
Crying	17.68	14.41	31	29313	23012	79692032
Sleep terror	17.66	14.41	14	29330	4444	79710600
Swelling face	17.62	14.41	62	29282	71150	79643894
Muscular weakness	17.49	14.41	20	29324	160709	79554335
Musculoskeletal pain	17.29	14.41	8	29336	102346	79612698
Psoriatic arthropathy	16.83	14.41	4	29340	77995	79637049
Blood viscosity abnormal	16.71	14.41	5	29339	174	79714870
Bronchopleural fistula	16.58	14.41	7	29337	672	79714372
Stomatitis	16.25	14.41	18	29326	146739	79568305
Pain in extremity	16.19	14.41	74	29270	364464	79350580
Therapeutic product effect incomplete	16.10	14.41	17	29327	141628	79573416
Lymphopenia	16.00	14.41	35	29309	30522	79684522
Rheumatoid arthritis	15.91	14.41	33	29311	208437	79506607
Hepatic function abnormal	15.86	14.41	61	29283	73046	79641998
Placental necrosis	15.71	14.41	3	29341	13	79715031
Hypokalaemia	15.58	14.41	18	29326	144022	79571022
Right atrial dilatation	15.55	14.41	7	29337	784	79714260
Legionella infection	15.39	14.41	7	29337	803	79714241
Wheezing	15.34	14.41	84	29260	116580	79598464
Obliterative bronchiolitis	15.30	14.41	11	29333	3017	79712027
Oedema peripheral	15.29	14.41	45	29299	252243	79462801
Encephalopathy	15.25	14.41	57	29287	67340	79647704
Arthritis	15.18	14.41	12	29332	114868	79600176
Drug-induced liver injury	15.03	14.41	56	29288	66061	79648983
Coronary artery disease	14.85	14.41	3	29341	65471	79649573
Balance disorder	14.82	14.41	9	29335	98848	79616196
Idiosyncratic drug reaction	14.69	14.41	8	29336	1349	79713695
Thinking abnormal	14.65	14.41	21	29323	13140	79701904
Upper respiratory tract inflammation	14.56	14.41	12	29332	4023	79711021
Shock	14.51	14.41	42	29302	43506	79671538
Anaemia	14.50	14.41	100	29244	444915	79270129

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AH02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Neuraminidase inhibitors
FDA MoA	N0000175436	Neuraminidase Inhibitors
FDA EPC	N0000175524	Neuraminidase Inhibitor
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:52425	acetylneuraminidase inhibitors
CHEBI has role	CHEBI:78298	environmental contaminants
CHEBI has role	CHEBI:83399	marine xenobiotic metabolites
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Influenza	indication	6142004	DOID:8469
Coronavirus infection	off-label use	186747009
Delirium	contraindication	2776000
Suicidal thoughts	contraindication	6471006
Acute nephropathy	contraindication	58574008
Impaired cognition	contraindication	386806002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.54	acidic
pKa2	7.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Neuraminidase	Enzyme	NRAM_INBLE	INHIBITOR	Ki	8.96	CHEMBL	CHEMBL
Neuraminidase	Enzyme	NRAM_I34A1	INHIBITOR	IC50	8.15	CHEMBL	CHEMBL
Neuraminidase	Enzyme	B4URF0_9INFA		IC50	10.22	CHEMBL
Sialidase	Enzyme	NANH_CLOPF		IC50	9	CHEMBL
Neuraminidase	Enzyme	NRAM_I68A0		IC50	8.81	CHEMBL
Neuraminidase	Enzyme	Q6Q793_9INFA		Ki	10	CHEMBL
Neuraminidase	Enzyme	A5Z252_9INFA		Ki	8.10	CHEMBL
Neuraminidase	Enzyme	Q2LFS1_9INFA		Ki	8.31	CHEMBL
Neuraminidase	Enzyme	C4LRQ6_9INFA		Ki	8.96	CHEMBL
Neuraminidase	Enzyme	Q20MD3_9INFA		IC50	8.54	CHEMBL
Neuraminidase	Enzyme	NRAM_I33A0		IC50	6.32	CHEMBL
Neuraminidase	Enzyme	Q194T1_9INFA		IC50	6.10	CHEMBL
Neuraminidase	Enzyme	NRAM_I77AB		IC50	8.86	CHEMBL
Neuraminidase	Enzyme	NRAM_I63A3		IC50	8.05	CHEMBL
Neuraminidase	Enzyme	NRAM_I71A1		IC50	9.96	CHEMBL
Neuraminidase	Enzyme	NRAM_I77AG		IC50	7.82	CHEMBL
Neuraminidase	Enzyme	NRAM_I79A0		IC50	9.83	WOMBAT-PK
Neuraminidase	Enzyme	NRAM_I72A8		IC50	6.24	CHEMBL
Neuraminidase	Enzyme	NRAM_INBVI		IC50	8.10	WOMBAT-PK

External reference:

ID	Source
4021189	VUID
N0000175097	NUI
D00900	KEGG_DRUG
204255-11-8	SECONDARY_CAS_RN
4021189	VANDF
4021190	VANDF
C0874161	UMLSCUI
CHEBI:7798	CHEBI
CHEBI:73139	CHEBI
G39	PDB_CHEM_ID
CHEMBL1229	ChEMBL_ID
CHEMBL674	ChEMBL_ID
DB00198	DRUGBANK_ID
CHEMBL1200340	ChEMBL_ID
D053139	MESH_DESCRIPTOR_UI
65028	PUBCHEM_CID
11427	IUPHAR_LIGAND_ID
C535162	MESH_SUPPLEMENTAL_RECORD_UI
7793	INN_ID
20O93L6F9H	UNII
DB02600	DRUGBANK_ID
1546279	RXNORM
247129	MMSL
31447	MMSL
8475	MMSL
d04462	MMSL
007918	NDDF
007919	NDDF
116113006	SNOMEDCT_US
386142008	SNOMEDCT_US
412261005	SNOMEDCT_US
C2713885	UMLSCUI
187227-45-8	SECONDARY_CAS_RN
449381	PUBCHEM_CID
K6106LV5Q8	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tamiflu	HUMAN PRESCRIPTION DRUG LABEL	1	0004-0800	CAPSULE	75 mg	ORAL	NDA	28 sections
Tamiflu	HUMAN PRESCRIPTION DRUG LABEL	1	0004-0801	CAPSULE	45 mg	ORAL	NDA	28 sections
Tamiflu	HUMAN PRESCRIPTION DRUG LABEL	1	0004-0802	CAPSULE	30 mg	ORAL	NDA	28 sections
Tamiflu	HUMAN PRESCRIPTION DRUG LABEL	1	0004-0822	POWDER, FOR SUSPENSION	6 mg	ORAL	NDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8180	POWDER, FOR SUSPENSION	6 mg	ORAL	ANDA	29 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8180	POWDER, FOR SUSPENSION	6 mg	ORAL	ANDA	29 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4591	CAPSULE	30 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4592	CAPSULE	45 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4593	CAPSULE	75 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-5137	SUSPENSION	30 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	16714-817	CAPSULE	30 mg	ORAL	ANDA	25 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	16714-818	CAPSULE	45 mg	ORAL	ANDA	25 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	16714-819	CAPSULE	75 mg	ORAL	ANDA	25 sections
Oseltamivir phosphate	Human Prescription Drug Label	1	27241-139	FOR SUSPENSION	6 mg	ORAL	ANDA	25 sections
Oseltamivir phosphate	Human Prescription Drug Label	1	27241-139	FOR SUSPENSION	6 mg	ORAL	ANDA	25 sections
Oseltamivir phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-108	POWDER, FOR SUSPENSION	6 mg	ORAL	ANDA	29 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	31722-630	CAPSULE	30 mg	ORAL	ANDA	25 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	31722-631	CAPSULE	45 mg	ORAL	ANDA	25 sections
Oseltamivir Phosphate	Human Prescription Drug Label	1	31722-632	CAPSULE	75 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-256	CAPSULE	30 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-256	CAPSULE	30 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-257	CAPSULE	45 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-257	CAPSULE	45 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-258	CAPSULE	75 mg	ORAL	ANDA	25 sections
oseltamavir phosphate	Human Prescription Drug Label	1	33342-258	CAPSULE	75 mg	ORAL	ANDA	25 sections
Tamiflu	HUMAN PRESCRIPTION DRUG LABEL	1	42254-092	POWDER, FOR SUSPENSION	6 mg	ORAL	NDA	30 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-567	FOR SUSPENSION	6 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-567	FOR SUSPENSION	6 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-567	FOR SUSPENSION	6 mg	ORAL	ANDA	28 sections
Oseltamivir Phosphate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-664	CAPSULE	75 mg	ORAL	ANDA	27 sections